Life Sciences Platform
Good morning, John
What research would you like to work on today?
23
Monday, March 2026
Evidence Hub
Your intelligent research drive. Save articles, folders & evidence from any service across MadeAI.
Literature Review
Systematic reviews, meta-analyses & evidence synthesis across major life sciences databases.
Quick Research
Rapid literature searches with instant results from PubMed, Embase & Cochrane in seconds.
Medical Information Request
AI-structured responses to HCP & patient MIR queries. Sourced, cited & compliance-ready.
EU HTA
Joint Clinical Assessment
EU HTA JCA evidence packages, comparative clinical assessments & relative effectiveness dossiers.
HTA Ready
Dossier Xpert
Regulatory dossier preparation, submission-ready reports & evidence packages for HTA bodies.
Oncology
10 folders
Edit
Download
Add Collaborator
Delete
Xarelto
29 articles
Edit
Download
Add Collaborator
Delete
Opsumit
36 articles
Edit
Download
Add Collaborator
Delete
Opsynvi
123 articles
Edit
Download
Add Collaborator
Delete
Tracleer
7,343 articles
Edit
Download
Add Collaborator
Delete
Uptravi
48 articles
Edit
Download
Add Collaborator
Delete
Veletri
15 articles
Edit
Download
Add Collaborator
Delete
Keytruda
35 articles
Edit
Download
Add Collaborator
Delete
Opdivo
33 articles
Edit
Download
Add Collaborator
Delete
Avastin
12 articles
Edit
Download
Add Collaborator
Delete
Ibrutinib
41 articles
Cardiology
4 folders
Edit
Download
Add Collaborator
Delete
Eliquis
88 articles
Edit
Download
Add Collaborator
Delete
Entresto
54 articles
Edit
Download
Add Collaborator
Delete
Repatha
31 articles
Edit
Download
Add Collaborator
Delete
Verquvo
19 articles
Neurology / CNS
3 folders
Edit
Download
Add Collaborator
Delete
Ocrevus
62 articles
Edit
Download
Add Collaborator
Delete
Spinraza
44 articles
Edit
Download
Add Collaborator
Delete
Leqembi
27 articles
Immunology & Inflammation
5 folders
Edit
Download
Add Collaborator
Delete
Dupixent
91 articles
Edit
Download
Add Collaborator
Delete
Humira
156 articles
Endocrinology & Metabolism
2 folders
Edit
Download
Add Collaborator
Delete
Ozempic
78 articles
Edit
Download
Add Collaborator
Delete
Jardiance
43 articles
Infectious Diseases
3 folders
Edit
Download
Add Collaborator
Delete
Paxlovid
52 articles
Gastroenterology
4 folders
Edit
Download
Add Collaborator
Delete
Stelara
67 articles
Edit
Download
Add Collaborator
Delete
Skyrizi
38 articles
132
Total Articles
3
Collaborators
Mar 14
Last Updated
Folders
DEFAULT
Literature Articles
Published research, clinical trials & systematic reviews
87 articles
May 14, 2025
| Article Title | File Name | Owner | Files | Last Modified Date | Action |
|---|---|---|---|---|---|
|
Flunarizine as prophylaxis for episodic migraine: a systematic review with meta-analysis
|
flunarizine_migraine_SR_2024.pdf
|
Andrew Taylor | Nov 19 2024 04:55 PM |
Download
Delete
|
|
|
Post-Authorization Observational Study of the Safety Profile of Zelidafen in Routine Clinical
Settings
|
zelidafen_safety_PAS_2024.pdf
|
Andrew Taylor | Nov 21 2024 06:31 PM |
Download
Delete
|
|
|
Comparative Real-World Effectiveness of Zelidafen Versus Standard Antiviral Therapy in
Hemotropic Fever
|
zelidafen_vs_standard_RWE.pdf
|
Andrew Taylor | Apr 21 2025 08:41 AM |
Download
Delete
|
|
|
Retrospective Analysis of Hospitalized Patients With Hemotropic Fever Treated With Zelidafen
Across Three Regional Centers
|
retrospective_hemotropic_3center.pdf
|
Andrew Taylor | May 14 2025 07:43 PM |
Download
Delete
|
|
|
Outcomes From the Hemotropic Fever Global Registry: Zelidafen-Associated Survival and Recovery
Metrics
|
HFGR_survival_recovery_2025.pdf
|
Andrew Taylor, Jordan Parker | May 14 2025 07:43 PM |
Download
Delete
|
|
|
Treatment Outcomes and Recovery Metrics with Zelidafen in Hemotropic Fever: Data from an
International Registry
|
zelidafen_intl_registry_outcomes.pdf
|
Andrew Taylor | Apr 21 2025 08:41 AM |
Download
Delete
|
|
|
Xarelto in Non-Valvular Atrial Fibrillation: 5-Year Real-World Outcomes from a Nordic Cohort
|
xarelto_af_nordic_5yr.pdf
|
Sarah Chen | Mar 18 2025 10:15 AM |
Download
Delete
|
|
|
Rivaroxaban Dosing Adjustments in CKD: Systematic Review and Clinical Guidance
|
rivaroxaban_CKD_dosing_SR.pdf
|
Andrew Taylor | Mar 5 2025 09:00 AM |
Download
Delete
|
|
|
Patient Outcomes in Hemotropic Fever: Findings from a Multinational Registry Study
|
multinational_registry_patient_outcomes.pdf
|
Andrew Taylor, Jordan Parker | Apr 21 2025 08:41 AM |
Download
Delete
|
|
|
Clinical Outcomes from the Hemotropic Fever Global Registry: Survival and Recovery Trends with
Zelidafen
|
HFGR_clinical_trends_zelidafen.pdf
|
Andrew Taylor | May 14 2025 07:43 PM |
Download
Delete
|
|
|
EINSTEIN DVT Extension Study: Long-Term Rivaroxaban for Prevention of Recurrent VTE
|
einstein_dvt_extension_LT.pdf
|
Jordan Parker | Feb 14 2025 03:22 PM |
Download
Delete
|
|
|
Cost-Effectiveness of Rivaroxaban Versus Enoxaparin in Hip and Knee Arthroplasty: HTA
Submission Analysis
|
rivaroxaban_ortho_CEA_HTA.pdf
|
Sarah Chen | Jan 30 2025 11:05 AM |
Download
Delete
|
Recent Chats
Xarelto RCT comparison — abrocitinib vs dupilumab
Oncology folder — evidence landscape summary
Immunology articles updated in last 30 days
Phase III trials in Cardiology category
Rivaroxaban safety data — CKD dose adjustments
EINSTEIN DVT Extension — key findings
Neurology / CNS folder overview
Collaborators across all Oncology folders
Ask MadeAI
Request Management
Manage incoming medical information requests, track status, assign responders and generate AI-powered responses.
Guidelines
Browse region-specific medical information guidelines, regulatory frameworks, and compliance requirements.
Standard Response Management
Create, manage, and browse pre-approved standard responses for common medical information queries by region.
Total Requests
247
All time across regions
+12% this month
Resolved
189
76.5% resolution rate
+5% vs last month
In Progress
41
Avg 2.4 days to resolve
Steady
AI Responses
134
54.3% AI-assisted
Growing adoption
| Req ID | Product | Request | Type | Status | Requested On | Requested By | Action |
|---|
Create Standard Response
Clinical Efficacy
Response Title
MIR ID
—
Articles Referenced
—
Product
—
Region
—
Response Content
Used
—
Last Updated
—
Referenced Articles
Response
AI Generated
Click "AI Analyse" above to get response options, or start typing here.
Last Updated By: Alfred K Joy 23 Mar 2024
References
Generate an AI response to see referenced articles here.
Previous Responses
Similar requests previously handled by the team
FDA
Guideline Title
Overview
Key Requirements
Applicability
This guideline applies to all pharmaceutical companies operating in the region and covers medical information activities including written and verbal responses to unsolicited healthcare professional inquiries.
Similar Requests
2 similar requests found
MadeAI Responses
12 templates available
Standard
Similar
MadeAI
Protocol
Search
Deduplication
Title & Abstract
Full-text
Study Title
Objective / Review Question
PICOS Criteria
Proquest Dialog
| Element | Inclusion | Exclusion |
|---|---|---|
| Population (P) | ||
| Intervention (I) | ||
| Comparator (C) | ||
| Outcomes (O) | ||
| Study Design (S) |
Inclusion / Exclusion Criteria
Additional Inclusion Criteria
Additional Exclusion Criteria
Analysis complete
We found relevant response options for this request.
Abstract Research
Source References
Source references
will appear here after your search
All Projects
Manage and track all your systematic review projects
Filter projects
Stage
All
Protocol
Search
Dedup
Screen
Extract
Report
Progress
Any
0 to 33%
34 to 66%
67 to 100%
| Project ID | Project Name | Created Date | Modified Date | Progress | Stage | Actions |
|---|
No results
Protocol
Search
Deduplication
(Unique articles = 242)
Screen
Title and Abstract
Full-text
Extract
(All Articles = 242)
Report
Protocol Index
1Study Title
2Review Questions
3PICOS Criteria
4Inclusion/Exclusion Criteria
5PubMed Search Query
6Preview Protocol
Step 1 of 6 · Protocol
Study Title
Confirm the working title of your systematic review. This appears across every downstream stage and on the final report.
Study Title
Step 2 of 6 · Protocol
Objective(s) / Review Question(s)
State the primary and secondary objectives that frame the review.
Primary Objective
Secondary Objectives
Step 3 of 6 · Protocol
PICOS Criteria
The Population, Intervention, Comparator, Outcomes and Study-design that scope your search.
| Population (P) | Patients with gastric cancer Individuals at risk for gastric cancer General population for epidemiological analysis |
| Intervention (I) | Surgical resection Chemotherapy Radiotherapy Targeted therapy Immunotherapy |
| Comparator (C) | Different treatment modalities Standard care Placebo No treatment Regional variations in treatment approaches |
| Outcomes (O) | Incidence rates Prevalence rates Mortality rates Overall survival Disease-free survival |
| Study Design (S) | Systematic reviews Meta-analyses Cohort studies Case-control studies Cross-sectional studies |
Step 4 of 6 · Protocol
Inclusion / Exclusion Criteria
Advanced (custom) criteria, grouped by topic. These drive AI screening at the Title & Abstract and Full-text stages.
PopulationRemove Topic
Sub-topicInclusionExclusion
Disease / condition
Patients with gastric cancer
Gastric adenocarcinoma
Stomach cancer
Gastric malignancy
Gastric adenocarcinoma
Stomach cancer
Gastric malignancy
Non-gastric malignancies
Benign gastric conditions
Gastric polyps without malignancy
Other gastrointestinal cancers
Benign gastric conditions
Gastric polyps without malignancy
Other gastrointestinal cancers
Other population
Individuals at risk for gastric cancer
General population for epidemiological analysis
High-risk populations
General population for epidemiological analysis
High-risk populations
Populations without gastric-cancer risk assessment
Non-representative population samples
Non-representative population samples
InterventionRemove Topic
Sub-topicInclusionExclusion
Treatment approaches
Surgical resection, gastrectomy, endoscopic resection
Chemotherapy (neoadjuvant / adjuvant)
Radiotherapy, chemoradiotherapy
Targeted therapy (anti-HER2, anti-VEGF)
Immunotherapy, checkpoint inhibitors
Chemotherapy (neoadjuvant / adjuvant)
Radiotherapy, chemoradiotherapy
Targeted therapy (anti-HER2, anti-VEGF)
Immunotherapy, checkpoint inhibitors
Non-therapeutic interventions
Diagnostic procedures only
Screening interventions without treatment
Experimental treatments without established protocols
Diagnostic procedures only
Screening interventions without treatment
Experimental treatments without established protocols
OutcomesRemove Topic
Sub-topicInclusionExclusion
Efficacy
Overall survival, disease-free survival
Progression-free survival
Treatment / objective response rates
Progression-free survival
Treatment / objective response rates
Studies not reporting survival
Studies without efficacy endpoints
Studies without efficacy endpoints
Safety
Mortality rates, treatment-related mortality
Adverse events, toxicity profiles
Adverse events, toxicity profiles
Studies not reporting mortality / adverse events
Studies without safety assessment
Studies without safety assessment
Step 5 of 6 · Protocol
PubMed Search Query
Auto-generated Boolean strings per facet, combined into a final query. Edit any facet then regenerate.
| Facet | Sub-facet | ID | Query | Hits |
|---|---|---|---|---|
| Population | Disease / Condition | #1 | ("gastric cancer"[MeSH Terms] OR "gastric cancer"[All Fields] OR "gastric adenocarcinoma"[All Fields] OR "stomach cancer"[MeSH Terms]…) | 158,492 |
| Intervention | — | #2 | ("surgical resection"[All Fields] OR "gastrectomy"[MeSH Terms] OR "chemotherapy"[All Fields] OR "radiotherapy"[MeSH Terms] OR "targeted therapy"[All Fields]…) | 1,644,612 |
| Comparator | — | #3 | ("different treatment modalities"[All Fields] OR "standard of care"[All Fields] OR "placebo"[MeSH Terms] OR "no treatment"[All Fields]…) | 819,169 |
| Outcome | Efficacy | #4 | ("overall survival"[MeSH Terms] OR "disease-free survival"[All Fields] OR "progression-free survival"[All Fields] OR "response rate"[All Fields]…) | 397,150 |
| Outcome | Safety | #5 | ("mortality rates"[All Fields] OR "treatment-related mortality"[All Fields] OR "adverse events"[All Fields] OR "toxicity profiles"[All Fields]) | 377,991 |
| Study Design | Study design | #6 | ("systematic reviews"[Publication Type] OR "meta-analyses"[Publication Type] OR "cohort studies"[All Fields] OR "case-control studies"[All Fields]…) | 5,189,578 |
| Filters | — | #7 | ((2020/01/01:3000/01/01[pdat]) AND (humans[Filter]) AND (english[Filter])) | — |
| Final Query | — | #8 | (#1) AND (#2) AND (#3) AND (#4 OR #5) AND (#6) AND (#7) | 242 |
Step 6 of 6 · Protocol
Preview Protocol
The complete protocol in one scrollable view. Confirm to launch the Search stage.
Study Title
Epidemiology, Risk Factors, and Treatment Approaches in Gastric Cancer: A Comprehensive Review
Objectives
Primary: To provide a comprehensive review of the epidemiology, risk factors, and treatment approaches in gastric cancer.
Secondary: Analyze epidemiological patterns; identify risk factors; review treatment modalities; synthesize comparative effectiveness evidence.
Secondary: Analyze epidemiological patterns; identify risk factors; review treatment modalities; synthesize comparative effectiveness evidence.
PICOS Criteria
| Population | Patients with / at risk for gastric cancer; general population |
| Intervention | Surgery, chemo-, radio-, targeted & immunotherapy |
| Comparator | Standard care, placebo, no treatment, regional variation |
| Outcomes | Incidence, prevalence, mortality, overall & disease-free survival |
| Study Design | SRs, meta-analyses, cohort, case-control, cross-sectional |
Search & Eligibility
Advanced custom criteria across 5 topics · PubMed final query #8 returning 242 unique articles after deduplication · Filters: 2020–present, humans, English.
Step 1 of 6
0 of 5 regenerations used